These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 26002380)

  • 21. Current trends in epigenetic drug discovery.
    Stolfa DA; Einsle O; Sippl W; Jung M
    Future Med Chem; 2012 Oct; 4(16):2029-37. PubMed ID: 23157236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.
    Gabrielsson J; Green AR
    J Pharmacol Exp Ther; 2009 Dec; 331(3):767-74. PubMed ID: 19779129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of pharmacometrics to optimize biosimilar development.
    Dodds M; Chow V; Markus R; Pérez-Ruixo JJ; Shen D; Gibbs M
    J Pharm Sci; 2013 Nov; 102(11):3908-14. PubMed ID: 24027111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug development for cancer chemoprevention: focus on molecular targets.
    Johnson KA; Brown PH
    Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A toxicity risk index, an index for warning idiosyncratic drug toxicity.
    Morimoto M; Samizo K; Ohta S; Mizuma T
    J Pharm Sci; 2013 Sep; 102(9):3447-50. PubMed ID: 23666879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolving molecules using multi-objective optimization: applying to ADME/Tox.
    Ekins S; Honeycutt JD; Metz JT
    Drug Discov Today; 2010 Jun; 15(11-12):451-60. PubMed ID: 20438859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Addressing the challenges of low clearance in drug research.
    Di L; Obach RS
    AAPS J; 2015 Mar; 17(2):352-7. PubMed ID: 25567366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New drug design with covalent modifiers.
    Adeniyi AA; Muthusamy R; Soliman ME
    Expert Opin Drug Discov; 2016; 11(1):79-90. PubMed ID: 26757171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application and Impact of Human Dose Projection from Discovery to Early Drug Development.
    Patel D; Yang W; Lipert M; Wu T
    AAPS PharmSciTech; 2020 Jan; 21(2):44. PubMed ID: 31897807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Covalent Inhibition in Drug Discovery: Filling the Void in Literature.
    Bjij I; Olotu FA; Agoni C; Adeniji E; Khan S; El Rashedy A; Cherqaoui D; Soliman MES
    Curr Top Med Chem; 2018; 18(13):1135-1145. PubMed ID: 30068277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The integration of pharmacokinetics and pharmacodynamics: understanding dose-response.
    Abdel-Rahman SM; Kauffman RE
    Annu Rev Pharmacol Toxicol; 2004; 44():111-36. PubMed ID: 14744241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery.
    Feng B; Varma MV; Costales C; Zhang H; Tremaine L
    Expert Opin Drug Discov; 2014 Aug; 9(8):873-90. PubMed ID: 24857286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The design and development of covalent protein-protein interaction inhibitors for cancer treatment.
    Cheng SS; Yang GJ; Wang W; Leung CH; Ma DL
    J Hematol Oncol; 2020 Mar; 13(1):26. PubMed ID: 32228680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.
    Caruso A; Frances N; Meille C; Greiter-Wilke A; Hillebrecht A; Lavé T
    J Pharmacol Toxicol Methods; 2014; 70(1):73-85. PubMed ID: 24879942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of physiologically based pharmacokinetic modeling and simulation in drug development.
    Shardlow CE; Generaux GT; Patel AH; Tai G; Tran T; Bloomer JC
    Drug Metab Dispos; 2013 Dec; 41(12):1994-2003. PubMed ID: 24009310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Survey of Neonatal Pharmacokinetic and Pharmacodynamic Studies in Pediatric Drug Development.
    Wang J; Avant D; Green D; Seo S; Fisher J; Mulberg AE; McCune SK; Burckart GJ
    Clin Pharmacol Ther; 2015 Sep; 98(3):328-35. PubMed ID: 25975723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors.
    Ichimaru K; Toyoshima S; Uyama Y
    Clin Pharmacol Ther; 2010 Mar; 87(3):362-6. PubMed ID: 20107436
    [No Abstract]   [Full Text] [Related]  

  • 38. Regional intestinal drug permeation: biopharmaceutics and drug development.
    Lennernäs H
    Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toward molecular imaging-driven drug development in oncology.
    de Vries EG; Oude Munnink TH; van Vugt MA; Nagengast WB
    Cancer Discov; 2011 Jun; 1(1):25-8. PubMed ID: 22586317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The animal rule: The role of clinical pharmacology in determining an effective dose in humans.
    Bergman KL
    Clin Pharmacol Ther; 2015 Oct; 98(4):365-8. PubMed ID: 26082064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.